Atropine eye drops for myopia in young adults

• Atropine eye drops have multiple uses in eye care, from increasing eye examination accuracy to treatment for lazy eye in children, to managing eye inflammation in children and adults.
• In young adults, atropine 1% is occasionally used for the reasons described above.
• Atropine eye drops 0.01% to 0.05% for myopia control have evidence for use from age 4 until around age 15 to 16. There is no evidence for its use in older teenagers and young adults, and may have side effects which could impact vision for study and driving. 

Atropine is used in general medicine, and also as an eye medicine or eye drop. As an eye drop, atropine 1% is used to dilate (enlarge) the pupil and stop the eye’s focusing mechanism, which has applications for testing the vision and treating amblyopia (lazy eye) in young children, and also for treating some eye diseases in people of any age.⁸ These side effects are useful for these purposes but not desirable in long-term use for myopia control.

Atropine eye drops for myopia control have been researched in concentrations (strengths) from 0.01% right up to 1%. The lower concentrations have less side effects and 0.02% to 0.05% have so far shown the best balance of effective myopia control with minimal side effects.^9,10

Myopia, also known as short-sightedness or near-sightedness, causes vision to become blurred in the long distance, and the need for glasses or contact lenses to bring the eye back into focus.

Myopia is a lifelong condition and increases risk of potentially sight threatening conditions in later life, leading the World Health Organization to classify myopia as a global health concern.¹

In most cases, myopia starts in childhood, and then progressively increases typically up until early adulthood when it stabilizes.² For some people, though, myopia can still progress in the 20s, with over one-third showing some worsening of their myopia over that decade.^3-5

Myopia can also onset in early adulthood, after a childhood of normal vision. A large study which examined adults at age 20 and again at age 28 found that 14% developed myopia over that time.³

'Myopia control' has become the increasingly adopted term to describe the use of treatments aimed to slow progression of myopia. These treatments can include spectacles, contact lenses or atropine eye drops. Myopia control is particularly important in children and younger teenagers, because this is the stage in life when myopia is most likely to progress or worsen quickly.⁶

In young adults, myopia progression can occur but is less rapid and frequent than in kids and younger teens. This is partly because myopia progression starts to stabilize in the late teenage years, with half of young myopes naturally ceasing their myopia progression by age 16.² Hence, there is very little research on treatments to slow myopia progression in older teenagers and young adults, as most research is concentrated on the faster time of myopia progression in childhood.²

Despite this lack of available information, experts recommend that myopia control treatments which are commenced in childhood should ideally continue as long as possible,^6,7 and into early adulthood to have the best overall impact on slowing myopia progression.

Atropine eye drops for myopia control, in concentrations from 0.01% to 0.05%, have been researched in children aged from 4 to 14, for 2-3 years of treatment. This means the evidence exists for atropine's tolerance and effectiveness up to age 15-16.^9,10

Myopia in young adults firstly requires the blurred vision to be corrected with spectacles or contact lenses. Special types of spectacles or contact lenses can correct blurred vision and also control myopia progression, although there is limited evidence for effectiveness of myopia control past age 16, just as there is limited evidence for atropine eye drops.

Since research indicates that young adult myopia progression does occur, expert advice is that myopia control treatment should ideally continue into early adulthood where possible.⁷ If atropine eye drops have been started in childhood and are still tolerated well in early adulthood, they could be continued. There are other spectacle and contact lens options, though, which appear to work as well as atropine¹¹ without the potential impact on vision.

1. The impact of myopia and high myopia. Report of the Joint World Health Organization-Brien Holden Vision Institute Global Scientific Meeting on Myopia. 2015 (link)
2. Hou W, Norton TT, Hyman L, Gwiazda J; COMET Group. Axial Elongation in Myopic Children and its Association With Myopia Progression in the Correction of Myopia Evaluation Trial. Eye Contact Lens. 2018 Jul;44(4):248-259. (link)
3. Lee SS, Lingham G, Sanfilippo PG, Hammond CJ, Saw SM, Guggenheim JA, Yazar S, Mackey DA. Incidence and Progression of Myopia in Early Adulthood. JAMA Ophthalmol. 2022 Feb 1;140(2):162-169. (link)
4. Bullimore MA, Reuter KS, Jones LA, Mitchell GL, Zoz J, Rah MJ. The Study of Progression of Adult Nearsightedness (SPAN): design and baseline characteristics. Optom Vis Sci. 2006 Aug;83(8):594-604. (link)
5. Pärssinen O, Kauppinen M, Viljanen A. The progression of myopia from its onset at age 8-12 to adulthood and the influence of heredity and external factors on myopic progression. A 23-year follow-up study. Acta Ophthalmol. 2014 Dec;92(8):730-9. (link)
6. Gifford KL, Richdale K, Kang P, Aller TA, Lam CS, Liu YM, Michaud L, Mulder J, Orr JB, Rose KA, Saunders KJ, Seidel D, Tideman JWL, Sankaridurg P. IMI - Clinical Management Guidelines Report. Invest Ophthalmol Vis Sci. 2019 Feb 28;60(3):M184-M203. (link)
7. Bullimore MA, Richdale K. Myopia Control 2020: Where are we and where are we heading? Ophthalmic Physiol Opt. 2020 May;40(3):254-270. (link)
8. McLendon K, Preuss CV. Atropine. [Updated 2021 Sep 12]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: (link)
9. Yam JC, Zhang XJ, Zhang Y, Wang YM, Tang SM, Li FF, Kam KW, Ko ST, Yip BHK, Young AL, Tham CC, Chen LJ, Pang CP. Three-Year Clinical Trial of Low-Concentration Atropine for Myopia Progression (LAMP) Study: Continued Versus Washout: Phase 3 Report. Ophthalmology. 2022 Mar;129(3):308-321. (link)
10. Cui C, Li X, Lyu Y, Wei L, Zhao B, Yu S, Rong J, Bai Y, Fu A. Safety and efficacy of 0.02% and 0.01% atropine on controlling myopia progression: a 2-year clinical trial. Sci Rep. 2021 Nov 15;11(1):22267. (link)
11. Brennan NA, Toubouti YM, Cheng X, Bullimore MA. Efficacy in myopia control. Prog Retin Eye Res. 2021 Jul;83:100923. (link)
12. Gifford KL, Gifford P, Hendicott PL, Schmid KL. Zone of Clear Single Binocular Vision in Myopic Orthokeratology. Eye Contact Lens. 2020 Mar;46(2):82-90. (link)
13. González-Méijome JM, Carracedo G, Lopes-Ferreira D, Faria-Ribeiro MA, Peixoto-de-Matos SC, Queirós A. Stabilization in early adult-onset myopia with corneal refractive therapy. Cont Lens Anterior Eye. 2016 Feb;39(1):72-7. (link)